The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro

Priscilla B. Wyrick, Stephen T. Knight, Donald G. Gerbig, Jane E. Raulston, Carolyn H. Davis, Terry R. Paul, Daniel Malamud

Research output: Contribution to journalArticle

Abstract

Safe and effective vaginal microbicidal compounds are being sought to offer women an independent method for protection against transmission of sexually acquired pathogens. The purpose of this study was to examine the efficacy of two formulations of one such compound, C31G, against Chlamydia trachomatis serovar E alone, its host epithelial cell (HEC-1B) alone, and against chlamydiae-infected HEC-1B cells. Preexposure of isolated, purified infectious chlamydial elementary bodies (EB) to C31G, at pHs 7.2 and 5.7, for 1 h at 4°C resulted in reduced infectivity of EB for HEC-1B cells. Examination of the C31G-exposed 35S-EB on sodium dodecyl sulfate- polyacrylamide gel electrophoresis autoradiographs and by Western blotting revealed a C31G concentration-dependent and pH-dependent destabilization of the chlamydial envelope, resulting in the release of chlamydial lipopolysaccharide and proteins. Interestingly, when the host human genital columnar epithelial cells were infected with chlamydiae and then exposed to dilute concentrations of C31G which did not alter epithelial cell viability, chlamydial infectivity was also markedly reduced. C31G gained access to the developing chlamydial inclusion causing damage to or destruction of metabolically active reticulate bodies as well as apparent alteration of the inclusion membrane, which resulted in premature escape of chlamydial antigen to the infected epithelial surface. These studies show that the broad- spectrum antiviral and antibacterial microbicide C31G also has antichlamydial activity.

Original languageEnglish (US)
Pages (from-to)1335-1344
Number of pages10
JournalAntimicrobial Agents and Chemotherapy
Volume41
Issue number6
StatePublished - Jun 1997

Fingerprint

Chlamydia trachomatis
Chlamydia
Epithelial Cells
Anti-Infective Agents
C 31G
In Vitro Techniques
Sodium Dodecyl Sulfate
Antiviral Agents
Lipopolysaccharides
Polyacrylamide Gel Electrophoresis
Cell Survival
Western Blotting
Antigens
Membranes
Proteins

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Wyrick, P. B., Knight, S. T., Gerbig, D. G., Raulston, J. E., Davis, C. H., Paul, T. R., & Malamud, D. (1997). The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrobial Agents and Chemotherapy, 41(6), 1335-1344.

The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. / Wyrick, Priscilla B.; Knight, Stephen T.; Gerbig, Donald G.; Raulston, Jane E.; Davis, Carolyn H.; Paul, Terry R.; Malamud, Daniel.

In: Antimicrobial Agents and Chemotherapy, Vol. 41, No. 6, 06.1997, p. 1335-1344.

Research output: Contribution to journalArticle

Wyrick, PB, Knight, ST, Gerbig, DG, Raulston, JE, Davis, CH, Paul, TR & Malamud, D 1997, 'The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro', Antimicrobial Agents and Chemotherapy, vol. 41, no. 6, pp. 1335-1344.
Wyrick PB, Knight ST, Gerbig DG, Raulston JE, Davis CH, Paul TR et al. The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. Antimicrobial Agents and Chemotherapy. 1997 Jun;41(6):1335-1344.
Wyrick, Priscilla B. ; Knight, Stephen T. ; Gerbig, Donald G. ; Raulston, Jane E. ; Davis, Carolyn H. ; Paul, Terry R. ; Malamud, Daniel. / The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro. In: Antimicrobial Agents and Chemotherapy. 1997 ; Vol. 41, No. 6. pp. 1335-1344.
@article{c0f42f4664984e7099c5080f66cc5e6b,
title = "The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro",
abstract = "Safe and effective vaginal microbicidal compounds are being sought to offer women an independent method for protection against transmission of sexually acquired pathogens. The purpose of this study was to examine the efficacy of two formulations of one such compound, C31G, against Chlamydia trachomatis serovar E alone, its host epithelial cell (HEC-1B) alone, and against chlamydiae-infected HEC-1B cells. Preexposure of isolated, purified infectious chlamydial elementary bodies (EB) to C31G, at pHs 7.2 and 5.7, for 1 h at 4°C resulted in reduced infectivity of EB for HEC-1B cells. Examination of the C31G-exposed 35S-EB on sodium dodecyl sulfate- polyacrylamide gel electrophoresis autoradiographs and by Western blotting revealed a C31G concentration-dependent and pH-dependent destabilization of the chlamydial envelope, resulting in the release of chlamydial lipopolysaccharide and proteins. Interestingly, when the host human genital columnar epithelial cells were infected with chlamydiae and then exposed to dilute concentrations of C31G which did not alter epithelial cell viability, chlamydial infectivity was also markedly reduced. C31G gained access to the developing chlamydial inclusion causing damage to or destruction of metabolically active reticulate bodies as well as apparent alteration of the inclusion membrane, which resulted in premature escape of chlamydial antigen to the infected epithelial surface. These studies show that the broad- spectrum antiviral and antibacterial microbicide C31G also has antichlamydial activity.",
author = "Wyrick, {Priscilla B.} and Knight, {Stephen T.} and Gerbig, {Donald G.} and Raulston, {Jane E.} and Davis, {Carolyn H.} and Paul, {Terry R.} and Daniel Malamud",
year = "1997",
month = "6",
language = "English (US)",
volume = "41",
pages = "1335--1344",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - The microbicidal agent C31G inhibits Chlamydia trachomatis infectivity in vitro

AU - Wyrick, Priscilla B.

AU - Knight, Stephen T.

AU - Gerbig, Donald G.

AU - Raulston, Jane E.

AU - Davis, Carolyn H.

AU - Paul, Terry R.

AU - Malamud, Daniel

PY - 1997/6

Y1 - 1997/6

N2 - Safe and effective vaginal microbicidal compounds are being sought to offer women an independent method for protection against transmission of sexually acquired pathogens. The purpose of this study was to examine the efficacy of two formulations of one such compound, C31G, against Chlamydia trachomatis serovar E alone, its host epithelial cell (HEC-1B) alone, and against chlamydiae-infected HEC-1B cells. Preexposure of isolated, purified infectious chlamydial elementary bodies (EB) to C31G, at pHs 7.2 and 5.7, for 1 h at 4°C resulted in reduced infectivity of EB for HEC-1B cells. Examination of the C31G-exposed 35S-EB on sodium dodecyl sulfate- polyacrylamide gel electrophoresis autoradiographs and by Western blotting revealed a C31G concentration-dependent and pH-dependent destabilization of the chlamydial envelope, resulting in the release of chlamydial lipopolysaccharide and proteins. Interestingly, when the host human genital columnar epithelial cells were infected with chlamydiae and then exposed to dilute concentrations of C31G which did not alter epithelial cell viability, chlamydial infectivity was also markedly reduced. C31G gained access to the developing chlamydial inclusion causing damage to or destruction of metabolically active reticulate bodies as well as apparent alteration of the inclusion membrane, which resulted in premature escape of chlamydial antigen to the infected epithelial surface. These studies show that the broad- spectrum antiviral and antibacterial microbicide C31G also has antichlamydial activity.

AB - Safe and effective vaginal microbicidal compounds are being sought to offer women an independent method for protection against transmission of sexually acquired pathogens. The purpose of this study was to examine the efficacy of two formulations of one such compound, C31G, against Chlamydia trachomatis serovar E alone, its host epithelial cell (HEC-1B) alone, and against chlamydiae-infected HEC-1B cells. Preexposure of isolated, purified infectious chlamydial elementary bodies (EB) to C31G, at pHs 7.2 and 5.7, for 1 h at 4°C resulted in reduced infectivity of EB for HEC-1B cells. Examination of the C31G-exposed 35S-EB on sodium dodecyl sulfate- polyacrylamide gel electrophoresis autoradiographs and by Western blotting revealed a C31G concentration-dependent and pH-dependent destabilization of the chlamydial envelope, resulting in the release of chlamydial lipopolysaccharide and proteins. Interestingly, when the host human genital columnar epithelial cells were infected with chlamydiae and then exposed to dilute concentrations of C31G which did not alter epithelial cell viability, chlamydial infectivity was also markedly reduced. C31G gained access to the developing chlamydial inclusion causing damage to or destruction of metabolically active reticulate bodies as well as apparent alteration of the inclusion membrane, which resulted in premature escape of chlamydial antigen to the infected epithelial surface. These studies show that the broad- spectrum antiviral and antibacterial microbicide C31G also has antichlamydial activity.

UR - http://www.scopus.com/inward/record.url?scp=0030972780&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030972780&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 1335

EP - 1344

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -